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Introduction: Steroid hormones like androgens play an important role in the development and maintenance of
several brain functions. Androgens can act through androgen receptors (AR) in the brain. This study aims to dem-
onstrate the feasibility of positron emission tomography (PET) with 16β-[18F]ﬂuoro-5α-dihydrotestosterone
([18F]FDHT) to image AR expression in the brain.
Methods: Male Wistar rats were either orchiectomized to inhibit endogenous androgen production or
underwent sham-surgery. Fifteen days after surgery, rats were subjected to a 90-min dynamic [18F]FDHT PET
scan with arterial blood sampling. In a subset of orchiectomized rats, 1 mg/kg dihydrotestosterone was co-
injectedwith the tracer in order to saturate theAR. Plasma sampleswere analyzed for the presence of radioactive
metabolites by radio-TLC. Pharmacokineticmodelingwas performed to quantify brain kinetics of the tracer. After
the PET scan, the animals were terminated for ex-vivo biodistribution.
Results: PET imaging and ex vivo biodistribution studies showed low [18F]FDHT uptake in all brain regions,
except pituitary. [18F]FDHT uptake in the surrounding cranial bones was high and increased over time. [18F]
FDHT was rapidly metabolized in rats. Metabolism was signiﬁcantly faster in orchiectomized rats than in
sham-orchiectomized rats. Quantitative analysis of PET data indicated substantial spill-over of activity from
cranial bones into peripheral brain regions, which prevented further analysis of peripheral brain regions.
Logan graphical analysis and kinetic modeling using 1- and 2-tissue compartment models showed reversible
and homogenously distributed tracer uptake in central brain regions. [18F]FDHT uptake in the brain could not
be blocked by endogenous androgens or administration of dihydrotestosterone.
Conclusion: The results of this study indicate that imaging of AR availability in rat brain with [18F]FDHT PET is not
feasible. The low AR expression in the brain, the rapid metabolism of [18F]FDHT in rats and the poor brain
penetration of the tracer likely contributed to the poor performance of [18F]FDHT PET in this study.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Androgens, like testosterone, dihydrotestosterone (DHT) and
androstenedione, play a major role in the development and mainte-
nance of sexual characteristics in males. However, androgens are also
involved in maintenance of central nervous system functions and in
sexual differentiation of the brain in both males and females. In ageing
men, the levels of circulating androgens decrease as a result of
hypogonadism during a phase called the andropause. An imbalance
in the levels of circulating androgens and dysfunction of the
hypothalamic-pituitary-gonadal axis are associated with psychiatric
problems like mood disorders, psychosis and aggression [1,2]. Partial
androgen deﬁciency may lead to weakness, decreased libido anddicine and Molecular Imaging,
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7.erectile dysfunction, lower psychological vitality, depressive mood,
anxiety, insomnia, difﬁculty in concentrating and memory impairment.
These symptoms overlap with disease characteristics of major depres-
sion [3,4]. Testosterone treatment can enhance several aspects of
mood and cognition in hypogonadal men [5], it normalizes synaptic
neurogenesis, and it reduces depressive symptoms [6]. Still, the role of
reduced androgens in psychiatric problems, such asmood disorders, re-
mains largely unknown.
All androgens exert their activity through androgen receptors (AR),
which act as transcription factors and alter the expression of
androgen-responsive genes. These genes can affect different cellular
mechanisms involved in neurogenesis, cell death, cell migration, synap-
se formation, synapse elimination, and cell differentiation [7]. Despite
the role of AR in crucial processes in the healthy and diseased brain,
the expression of the receptor in the brain has not been widely studied
yet. This is likely due to the lack of validated tools for the non-invasive
assessment of AR expression in the living brain. Positron emission to-
mography (PET) is an imaging technique that can provide information
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manner, provided that a suitable tracer is available. 16β-[18F]ﬂuoro-
5α-dihydrotestosterone ([18F]FDHT) is an 18 F-labeled androgen
derivative that has been used successfully as a PET tracer for imaging
of AR expression in rats, baboons and patients with prostate cancer.
However, there are no studies reported yet on the use of [18F]FDHT
PET for imaging of AR expression in the brain [8]. The aim of this
study was therefore to investigate the feasibility of AR imaging in the
rat brain using [18F]FDHT PET. In addition, we investigated whether
the [18F]FDHT PET signal is inﬂuenced by endogenous or externally
administered androgens.
2. Materials and methods
2.1. Animals
Male out-bred Wistar-Unilever rats (13–15 weeks old, 300–400 g)
were obtained from Harlan (Horst, The Netherlands). The rats were
housed in groups in Macrolon cages with a layer of wood shavings. An-
imals were housed in a room with constant temperature (21 ± 2 °C),
and ﬁxed 12 h light–dark regime. Standard laboratory chow and water
were available ad libitum. After arrival, the rats were allowed to accli-
matize for at least 7 days. All experimentswere approved by the Institu-
tional Animal Care and Use Committee of the University of Groningen,
Groningen, the Netherlands (protocol number: DEC5842C).
2.2. Study design
Rats were orchiectomized to reduce the level of circulating andro-
gens that might compete with the PET tracer for the AR binding site
and a group of rats underwent sham-orchiectomy and normal circulat-
ing androgen levels were thus maintained. Twenty rats were included,
but 3 animals could not complete the whole study and therefore were
excluded: 1 rat died between surgery and the PET scan and arterial
blood sampling failed in 2 rats. One rat (sham-orchiectomized) was ex-
cluded from kinetic modeling only, since no reliable time activity curves
of the brain could be generated as a result of movement of the animal
during the PET scan.
Fifteen days after orchiectomy or sham-surgery, a 90-min dynamic
[18F]FDHT PET scan with arterial blood sampling was acquired. Half of
the orchiectomized rats were injected with the PET tracer mixed with
1 mg/kg dihydrotestosterone (ORC + DHT; n = 6) as a competitor for
binding to the AR in the brain. The remaining orchiectomized (ORC;
n = 6) rats received the tracer mixed with vehicle and were used as
controls. The sham-orchiectomized animals (Sham ORC; n = 5)
received the tracer mixed with vehicle only. After the PET scan, the
animals were terminated for ex-vivo biodistribution or analysis of
radioactive metabolites in the brain.
2.3. Orchiectomy
Orchiectomy was performed under anesthesia (5% isoﬂurane in
oxygen for induction and 2.5% for maintenance). Rats were placed in a
supine position exposing the testes. A surgical incision of about 1 cm
wasmade onmidline of the scrotum, and the skin of scrotumwaspulled
towards each lateral side to expose the testes in the tunica vaginalis. A
small oriﬁce was made by pulling the tunica vaginalis, and the testes
were exteriorized along with epididymis and vas deferens. The blood
vessels supplying the testes (arteries and veins) from the top and the
bottom were ligated and the testes along with the epididymis and the
vas deferens were removed. Biodegradable sutures were made in the
tunica vaginalis and the skin of midline scrotum. Immediately after sur-
gery rats received a subcutaneous injection of ﬁnadyne (2.5 mg/kg
Flunixin, Schering-Plough N.V/S.A., Belgium) for pain relief, and
administration of pain medication was repeated 24 h after surgery.
Rats were allowed to recover for 14 days, before they were subjectedto PET imaging. In the sham-orchiectomized group, the same surgical
procedure was performed, but without ligation of the blood vessels
and removal of the testes.
2.4. [18F]FDHT synthesis
[18F]FDHTwas produced bymodiﬁcation of the procedure described
by Liu et al. 1992 [9] (Fig. 1). Cyclotron-produced [18F]ﬂuoride was
trapped on a QMA anion exchange cartridge (Waters). The cartridge
was elutedwith a solution consisting of 0.2ml of a 5mg/ml aqueous po-
tassium carbonate solution and 0.7 ml of a 15 mg kryptoﬁx[2.2.2] solu-
tion in acetonitrile. The eluate containing the K[18F]-kryptoﬁx complex
was dried by azeotropic distillation with dry acetonitrile (3×0.5 ml).
After drying, a solution of 2 mg of the triﬂate precursor (Fig. 1) in
0.5 ml of dry acetonitrile was added. The reaction mixture was heated
at 55 °C for 5 min and subsequently the solvent was evaporated at
70 °C for 10 minutes. A solution of 5 mg of sodium borohydride in
1 ml of ethanol was added at 30 °C. After 5 min, 0.5 ml of 1 M HCl was
slowly added and the product was hydrolyzed for 15 min at 85 °C. The
mixture was then passed through an Alumina N cartridge and an
Acrodisc 1.2 μm ﬁlter in order to remove the free [18F]ﬂuoride and pre-
cipitated particles. Via the cartridge and ﬁlter, 300 mg sodium acetate
trihydrate in 0.8 ml of water was added to the eluate for neutralization.
The mixture was puriﬁed by HPLC (SymmetryPrep C18 column (7 μ,
7.8×300 mm), eluent: 42% acetonitrile in water, ﬂow 4 ml/min). [18F]
FDHT, with a retention time of approximately 15 min, was collected
and diluted into 50 ml of water. The solution was then applied to an
Oasis HLB 1 cc (30 mg) cartridge and the cartridge was washed with
3×5 ml of water. The ﬁnal product was eluted with 1 ml of ethanol
and 10 ml of 0.9% NaCl. The product was sterilized by ﬁltration over a
0.22 μm LG ﬁlter and collected in a 25 ml sterile vial. Quality control
was performed by Ultra-high performance chromatography (UPLC)
(column: Acquitiy UPLC BEH C18 (1.7 μ, 2.1×50mm, eluent: 30% aceto-
nitrile in water). The identity of [18F]FDHT was veriﬁed by co-elution
with an authentic reference sample. For the ﬁnal formulation for
in vivo experiments, the tracer was diluted with saline and
reconstituted with 30% beta-cyclodextrin.
2.5. PET acquisition
Rats were anesthetized with isoﬂurane mixed with medical air (5%
for induction and 2.5% for maintenance) and a catheter (0.8 mm o.d.;
0.4 mm i.d.) was inserted into the femoral vein for the injection of
[18F]FDHT and another catheter was inserted into the femoral artery
for blood sampling. After cannulation, the rats were positioned into
the PET scanner (Focus 220, Siemens Medical Solutions, USA, Inc.) in a
transaxial position with their heads in the center of the ﬁeld of view. A
transmission scan of 515 secondswith a 57Co point sourcewas obtained
for the correction of attenuation and scatter by tissue. After the trans-
mission scan was completed, 23 ± 12 MBq [18F]FDHT (speciﬁc activity
89 ± 56 GBq/nmol), mixed with either 30% beta-cyclodextrin or with
1 mg/kg DHT (Sigma-Aldrich, USA) in 30% beta-cyclodextrin, was
injected over a period of 1 min into the femoral vein cannula using an
infusion pump. Simultaneously with the injection of [18F]FDHT, an
emission scan of 90 min was started. During the PET acquisition 16
blood samples were collected to construct the plasma input function
and to determine the percentage of plasma metabolites.
2.6. Arterial blood sampling and metabolite analysis
Blood samples of approximately 100 μl were collected at approxi-
mately 10, 20, 30, 40, 50, 60, 90, 120, 180, 300, 450, 600, 900, 1800,
3600, and 5400 seconds after [18F]FDHT injection. After collection of
each blood sample, 0.1 ml of heparinized saline was injected to prevent
large changes in blood pressure. From the collected blood, 25 μl of blood
was collected separately to generate a whole blood activity curve. The
Fig. 1. Radiolabeling of [18F]FDHT.
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tivity in 25 μl of whole blood and in 25 μl of plasmawasmeasured using
a gamma counter (LKB Wallace, Turku, Finland). After the radioactivity
measurement, 50 μl of acetonitrile was added to the plasma samples in
order to precipitate the proteins. Hereafter, the mixture was vortexed
and centrifuged at 13,000 rpm for 5 min. Radioactivity in the superna-
tant and the pellet was measured to calculate recovery of activity (Re-
covery of activity = [Activity(supernatant)/(Activity(supernatant) +
Activity(pellet)] * 100%). An aliquot of 5 μl of the supernatant was ap-
plied on a silica gel TLC strip. The TLC strip was dried and run with an
eluting medium consisting of n-hexane and ethyl acetate (3:2). After
elution, the TLC strip was placed on a phosphor storage screen for
overnight exposure. The screen was read out with a Cyclone reader
and analyzed with OptiQuant software (OptiQuant version 03.00,
Packard Instrument Company) to calculate the percentages of intact
parent compound and metabolites. Metabolite analysis failed in 1
orchiectomized rat (without DHT treatment) due to technical reasons;
for this animal, a population based metabolite curve was generated
from the average metabolite curves of the other orchiectomized rats
(without DHT treatment).
2.7. PET image reconstruction and analysis
PET data were normalized and corrected for attenuation, scatter,
random coincidences and decay. The list-mode data of the emission
scans was separated into 23-frame sinograms (6×10, 4×30, 2×60,
1×120, 1×180, 4×300, 3×600 and 2×900 sec), which were iteratively
reconstructed (OSEM2D, 4 iterations, 16 subsets). PET image analysis
was performed using Inveon 4.0 software (Siemens Medical Solutions,
USA, Inc). The PET scan was manually co-registered with a T2 MRI
template. Regions of interest (ROI) were drawn around the amygdala,
bed nucleus of stria terminalis (BNST), brainstem, cerebellum,
frontal cortex, hippocampus, hypothalamus, midbrain, occipital/temporal/
parietal cortex (OTP Cortex), prefrontal cortex, pituitary gland, striatum,
thalamus, preoptic area, whole brain, frontal bone, and interparietal
bone on the MRI template and transferred to the co-registered PET
scans. Time-activity curves were generated for each region of interest.
In addition, the activity in the ROI during the last 15 min of the scan
was measured (75–90 min) and converted into standardized uptake
values (SUV) by normalization for body weight and injected tracer
dose. The SUV was deﬁned as: [tissue activity concentration (Bq/cm3)]/
[injected dose (Bq)/body weight (g)]. It was assumed that 1 cm3 of
brain tissue equals 1 g.
Kinetic modeling (compartment modeling and graphical analysis)
was used to quantify the brain uptake of [18F]FDHT, using whole blood
activity andmetabolite-corrected plasma activity as the input functions.For Logan graphical analysis a delay time (T*) of 10 min was applied,
whereas a 20 min delay time was used for Patlak analysis. Both the
one-tissue compartment model (1TCM) and the two-tissue reversible
compartment model (2TRCM) were evaluated, using a ﬁxed blood vol-
ume of 3.6%. Both compartment models were used to calculate the vol-
ume of distribution (VT):
1TCRM : VT ¼
K1
k2
2TCRM : VT ¼
K1
k2
 
 1þ k3
k4
 
The 2TCRM was also used to determine the non-displaceable
binding potential (BPND):
BPND ¼
k3
k4
2.8. Ex vivo biodistribution
After the 90-min PET scan, rats were sacriﬁced by extirpation of the
heart while under deep anesthesia. The brain and major peripheral tis-
sues were isolated. One hemisphere of the brain was dissected into spe-
ciﬁc brain regions; the other hemisphere was used for metabolite
analysis. Blood was centrifuged (6000×g for 5 min) to collect a plasma
sample. The tissue and plasma samples were weighed and analyzed for
the amount of radioactivity with a gamma counter (LKB-Wallac, Turku,
Finland). Tracer uptake was expressed as SUV.
2.9. Brain metabolite analysis
Ninety min after tracer injection, the remaining brain hemisphere
was weighed and cut into small pieces. Two volumes of acetonitrile
were added and the tissue was homogenized for 2 min. The homoge-
nate was centrifuged at 13,000 rpm for 5 min to remove the particulate
cell debris. A sample of the supernatant was collected and analyzed for
the presence of radiolabeled metabolites by TLC, as describe above for
the analysis of plasma samples.
2.10. Statistical analysis
All data are expressed asmean± standard error of themean (SEM).
Statistical analysis was performed using IBM SPSS statistics 22. Data
were analyzed by one-way ANOVA with groups as factor and brain
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separately for the distribution phase (0–3 min) and the elimination
phase (3–90 min) using a repeated measures ANOVA, with group as
the between-subject factor and time as the within-subject factor.
ANOVA was followed by a Tukey post-hoc test to correct for multiple
comparisons. Signiﬁcance was reached when the probability (p-value)
was b0.05.
3. Results
3.1. [18F[FDHT synthesis
The synthesis of [18F]FDHT was based on the method described by
Liu et al., 1992 [9]. In our hands, the published method was not readily
applicable for automation, because of the use of low temperatures and
moisture-sensitive reagents. Therefore, the labeling procedure was ad-
justed to allow fully automated production using a disposable
cassette-based synthesis module. [18F]FDHT was reliably synthesized,
although with a low radiochemical yield of 4.3 ± 1.6%. The product
radiochemical purity of 96 ± 3% and a speciﬁc activity of 130 ±
30 MBq/nmol. The main impurity – if present – was the 16α-isomer
of [18F]FDHT.
3.2. Ex-vivo biodistribution
The results of the ex-vivo brain distribution of [18F]FDHT at 90 min
after tracer injection are presented in Table 1. In all groups, [18F]FDHT
uptake was highest in pituitary, whereas very low uptakewas observed
in all other brain regions. Tracer uptake in sham-orchiectomized rats
was about 2-fold higher than in the other groups. However, statistical
analysis by one-way ANOVA followed by a Tukey posthoc test could
not reveal any signiﬁcant differences in tracer uptake between groups
for any of the brain regions. Ex-vivo biodistribution in peripheral organs
showed highest tracer uptake (SUV N 1) in excretory organs (kidney,
bladder, liver, stomach, duodenum, small intestine), prostate and bone
in all groups. However, statistical analysis did not reveal any signiﬁcant
differences in tracer uptake between groups either.
3.3. PET imaging
A representative [18F]FDHT PET image of the brain of an
orchiectomized rat is presented in Fig. 2A. Rats of all groups showed
low uptake of activity in the brain and high uptake in the surrounding
cranial bones. The average time-activity curves (TACs) of the whole
brain and interparietal bone are presented in Fig. 2B and C. The [18F]Table 1
Ex vivo brain distribution of [18F]FDHT 90 min post injection in orchietomized rats (ORC,
n = 6), orchiectomized rats co-injected with 1 mg/kg dihydrotestosterone (ORC + DHT,
n = 6) and sham-orchietomized rats (Sham ORC, n = 5). Results are expressed as
standardized uptake values (mean ± SEM). Data were analyzed by one-way ANOVA
followed by a Tukey post hoc test. No signiﬁcant differences (p b 0.05) between groups
were observed. OTP cortex: Occipital, temporal, parietal cortex.
Brain region ORC ORC + DHT Sham ORC
Amygdala 0.019 ± 0.005 0.057 ± 0.011 0.102 ± 0.050
Bulbus olfactorius 0.048 ± 0.014 0.068 ± 0.012 0.072 ± 0.010
Cerebellum 0.040 ± 0.010 0.054 ± 0.008 0.149 ± 0.085
Cingulate Cortex 0.022 ± 0.005 0.052 ± 0.010 0.103 ± 0.047
Entorhinal Cortex 0.037 ± 0.014 0.087 ± 0.031 0.107 ± 0.038
Frontal Cortex 0.034 ± 0.014 0.041 ± 0.007 0.094 ± 0.043
Hippocampus 0.036 ± 0.016 0.043 ± 0.007 0.100 ± 0.042
Hypothalamus 0.049 ± 0.016 0.088 ± 0.031 0.138 ± 0.042
Medulla 0.048 ± 0.016 0.057 ± 0.008 0.135 ± 0.067
OTP Cortex 0.032 ± 0.010 0.040 ± 0.006 0.104 ± 0.048
Pituitary 0.241 ± 0.064 0.241 ± 0.052 0.552 ± 0.166
Pons 0.044 ± 0.012 0.057 ± 0.011 0.117 ± 0.041
Striatum 0.034 ± 0.015 0.058 ± 0.017 0.098 ± 0.047
Thalamus 0.035 ± 0.013 0.050 ± 0.012 0.131 ± 0.064
Fig. 2. (A) Representative coronal (left) and sagittal (right) [18F]FDHT PET images of a rat
brain. Images consist of the summed data from 50–90 min after tracer injection in a ORC
rat. PET images are co-registeredwith anMRI template for anatomical reference. Time ac-
tivity curves of [18F]FDHT (standardized uptake value; mean ± SEM) in the whole brain
(B) and interparietal bone (C) in orchiectomized rats (ORC, n = 6), orchiectomized rats
co-injected with 1 mg/kg dihydrotestosterone (ORC + DHT, n = 6) and sham-
orchietomized rats (Sham ORC, n = 5). No signiﬁcant differences were observed in the
time-activity curves in the whole brain. In contrast, [18F]FDHT uptake in cranial bone
was signiﬁcantly higher in the distribution phase (3–90 min) in sham-orchiectomized
rats than in orchiectomized rats (p b 0.05).FDHT uptake in the brain peaked around 1.5 min, followed by a rapid
washout. [18F]FDHT uptake in the whole brain was not signiﬁcantly dif-
ferent between groups at any time point (e.g. SUV(75–90 min): 0.16 ±
0.03, 0.26 ± 0.06 and 0.37 ± 0.09 for orchiectomized rats,
orchiectomized rats treated with DHT and sham-orchiectomized rats,
respectively (p = 0.09)). In contrast, statistical analysis of the tracer
uptake in the cranial bones revealed a signiﬁcant group effect in the
elimination phase (3–90 min; F(2,14) = 6.2, p b 0.05), but not in
the distribution phase (0–3 min). Tukey post-hoc analysis showed
that tracer uptake in the cranial bones was signiﬁcantly higher in
sham-orchiectomized rats than in orchiectomized animals.
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jection, PET imaging showed higher tracer uptake in brain regions locat-
ed close to cranial bones such as cerebellum, frontal cortex, prefrontal
cortex, and pituitary, than in centrally located brain regions (Table 2).
ANOVA followed by a posthoc Tukey test showed increased uptake in
the brain stem of sham-orchiectomized rats, as compared to both
orchiectomized groups (p b 0.05). This difference between groups is
likely due to spill-over effects from the surrounding cranial bones. To
avoid interference of spill-over effects, centrally located brain regions
were analyzed separately. After exclusion of brain regions located
close to cranial bones, still none of the centrally located brain regions
showed any signiﬁcant differences in tracer uptake between groups.
3.4. Plasma activity and metabolism
[18F]FDHT plasma clearance could be described well with a bi-
exponential function in all groups, with a short half-life in the distribu-
tion phase and a long half-life in the excretion phase (1.7 ± 0.3 and
12 ± 4 min; 3.9 ± 1.9 and 8 ± 4 min; 19 ± 10 and 3.4 ± 0.2 min for
orchiectomized rats, DHT-treated orchiectomized rats and sham-
orchiectomized rats, respectively). These differences in half-life
between groups were not statistically signiﬁcant.
[18F]FDHTwas rapidlymetabolized in all groups of rats (Fig. 3A). Sta-
tistical analysis (repeatedmeasures ANOVA) revealed signiﬁcant differ-
ences in the percentage of plasma metabolites between groups
(F(2,13) = 5.5, p b 0.05) in the elimination phase (3–90 min p.i.), but
not in the distribution phase (0–2 min p.i.). Tukey post-hoc analysis
showed a statistically signiﬁcant lower percentage of metabolites in
plasma during the elimination phase in sham-orchiectomized rats
than in DHT-treated orchiectomized rats (p b 0.05), whereas the differ-
ence between sham-orchiectomized rats and orchiectomized rats was
approaching signiﬁcance (p = 0.065). In the sham-orchiectomized
rats, 50% of the radioactivity in plasma still consisted of intact tracer
at about 15 min after tracer injection, whereas 50% of metabolism of
the tracer was already observed within 5 min in both groups of
orchiectomized rats.
The metabolite-corrected TACs of plasma are displayed in Fig. 3B. In
linewith the differences in [18F]FDHTmetabolism between groups, also
a statistically signiﬁcant group effect (F(2,13) = 5.4, p b 0.05) was ob-
served in elimination phase of the metabolite-corrected plasma TACs
(3–90 min p.i.), with a statistically signiﬁcant lower metabolite-Table 2
[18F]FDHT uptake 75–90 min post injection in various brain regions of orchietomized rats
(ORC, n = 6), orchiectomized rats co-injected with 1 mg/kg dihydrotestosterone
(ORC + DHT, n = 7) and sham-orchietomized orchiectomized (Sham ORC, n = 6) rats,
as determined by PET. Data are expressed as standardized uptake values
(mean ± SEM). Data were analyzed by one-way ANOVA followed by a Tukey post hoc
test. Signiﬁcant differences as compared to the orchiectomized group are indicated with
an asterisk: *p b 0.05. BNST: bed nucleus of stria terminalis, OTP cortex: Occipital, tempo-
ral, parietal cortex.
Brain region ORC ORC + DHT Sham ORC
Brain regions located centrally in the brain
Amygdala 0.10 ± 0.02 0.18 ± 0.03 0.27 ± 0.08
BNST 0.07 ± 0.02 0.09 ± 0.02 0.15 ± 0.03
Hippocampus 0.09 ± 0.02 0.13 ± 0.03 0.17 ± 0.03
Hypothalamus 0.09 ± 0.02 0.13 ± 0.03 0.26 ± 0.03
Midbrain 0.10 ± 0.02 0.13 ± 0.04 0.16 ± 0.02
Striatum 0.08 ± 0.02 0.11 ± 0.02 0.14 ± 0.03
Thalamus 0.05 ± 0.01 0.10 ± 0.02 0.11 ± 0.03
Preoptic Area 0.13 ± 0.03 0.21 ± 0.06 0.29 ± 0.06
Brain regions close to the cranial bones
Brainstem 0.10 ± 0.02 0.19 ± 0.04 0.28 ± 0.06*
Cerebellum 0.18 ± 0.03 0.30 ± 0.07 0.44 ± 0.12
Frontal Cortex 0.20 ± 0.04 0.27 ± 0.06 0.44 ± 0.12
OTP Cortex 0.18 ± 0.03 0.26 ± 0.06 0.40 ± 0.11
Prefrontal Cortex 0.23 ± 0.05 0.31 ± 0.07 0.46 ± 0.12
Pitutary 0.21 ± 0.04 0.37 ± 0.10 0.57 ± 0.17corrected plasma activity in the sham-orchiectomized group than in
both orchiectomized groups (Tukey posthoc test, p b 0.05). The distribu-
tion phase (0–2 min p.i.) of the metabolite-corrected plasma curve was
not statistically signiﬁcantly different between groups.
Analysis of [18F]FDHT metabolites in the brain was not successful,
because the signals of the intact tracer and its metabolites were below
the limit of quantiﬁcation as a result of the low brain uptake of
the tracer.
3.5. Graphical analysis
Graphical analysis of tracer kinetics in the brain was performed by
Patlak and Logan analysis using themetabolite-corrected plasma curves
as input function. Logan graphical analysis showed a good ﬁt (T* 10min,
r2 0.96 ± 0.00) for all centrally located brain regions in all groups, sug-
gesting that [18F]FDHT displays reversible kinetics in these regions. In
contrast, tracer kinetics in brain regions close to the cranial bones, like
prefrontal cortex, brainstem, cerebellum, pituitary, and frontal cortex
could be ﬁtted better by Patlak (T* 20 min, r2 0.96 ± 0.01) than by
Logan graphical analysis. The tracer kinetics in cranial bones were also
better described by Patlak than Logan graphical analysis. The irrevers-
ible binding in cranial bones suggests accumulation of free [18F]ﬂuoride
as a result of deﬂuorination of the tracer. Fig. 4 shows representative ex-
amples of Logan and Patlak plots of a brain region located close to crani-
al bone (occipital/parietal/temporal cortex; OTP Cortex), a centrally
located brain region (bed nucleus of stria terminalis; BNST) and the
interparietal bone. These results suggest that PET imaging of [18F]
FDHT uptake in brain regions in the vicinity of the cranial bones is sub-
stantially affected by spill-over effects from the cranial bones into the
brain. Sham-orchiectomized rats were most affected by spill-over,
since bone uptake is higher in this group of animals than in both
orchiectomized groups. To avoid spill-over effects, the brain regions
close to the cranial bones were excluded from further analysis. Logan
graphical analysis was used to calculate the VT in central brain regions
(Table 3). In all central brain regions, VT was highest in DHT-treated
orchiectomized rats, although the differences between groups
were not statistically signiﬁcant. The difference in VT in midbrain
between sham-orchiectomized rats (0.56 ± 0.07) and DHT-treated
orchiectomized rats (1.09 ± 0.17) approached signiﬁcance (one-way
ANOVA, Tukey posthoc test, p = 0.054).
3.6. Compartment modeling
Compartment modeling with the 1TCM and 2TRCM was used to
quantify the tracer kinetics in the central brain regions (Table 3). Kinetic
modeling with the 1TCM model provide VT values that were approxi-
mately 2-fold lower than those obtained by Logan graphical analysis.
The VT determined by the 1TCM did not show any statistically signiﬁ-
cant differences in VT between groups.
Application of the 2TRCM resulted in VT values that were generally
higher and showed more variability than VT calculated by the 1TCM.
The VT determined with the 2TRCM was not signiﬁcantly different be-
tween groups for any of the central brain regions. The 2TRCM was also
used to calculate the non-displaceable binding potential (BPND) for the
central brain regions. However, no signiﬁcant differences in PBND
between groups were observed either.
4. Discussion
[18F]FDHT is a PET tracer that was developed for imaging of AR ex-
pression in prostate cancer and the tracer has already been applied for
this purpose in several clinical studies [10,11]. So far, [18F]FDHT has
not been investigated as a probe for imaging of AR in the brain. In this
study, we therefore aimed to establish the feasibility of in vivo quantiﬁ-
cation of AR availability in the rat brain by [18F]FDHT PET.
Fig. 3. (A) Percentage of intact [18F]FDHT in plasma and (B) metabolite-corrected plasma curves of [18F]FDHT in orchiectomized rats (ORC, n = 5), orchiectomized rats co-injected with
1 mg/kg DHT (ORC+ DHT, n = 6) and sham-orchietomized rats (Sham ORC, n = 5) (mean± SEM). Sham-orchiectomized rats showed a signiﬁcantly higher percentage of intact tracer
and metabolite-corrected plasma curve in the elimination phase of the time-activity curve (3–90 min, p b 0.05).
566 M.A. Khayum et al. / Nuclear Medicine and Biology 42 (2015) 561–569Our PET imaging and ex vivo biodistribution studies showed that
[18F]FDHT uptake in the rat brain was low. The poor brain uptake of
[18F]FDHT may be explained by compromised penetration of the tracer
across the blood–brain barrier. In theory, [18F]FDHT should be
sufﬁciently lipophilic to passively diffuse into the brain. However, DHT
is a known substrate of P-glycoprotein [12]. P-glycoprotein is an efﬂux
transporter in the blood–brain barrier that can extrude a wide variety
of lipophilic compounds out of the brain. Because of the structural
similarities of [18F]FDHT and DHT, it is conceivable that the PET tracer
is also a P-glycoprotein substrate and consequently may not be able to
cross the blood–brain barrier. This hypothesis is in line with the obser-
vation that [18F]FDHT uptake was substantially higher in pituitary,
which is not protected by the blood–brain barrier [13], than in any
other brain region. On the other hand, the TACs of [18F]FDHT (Fig. 2B)
show a high peak uptake in the brain within 2 minutes after tracer in-
jection (SUV N2), suggesting that tracer delivery to the brain is not im-
paired. Moreover, the TAC of [18F]FDHT closely resembles the published
TAC of 3H-testosterone [14], which can readily cross the blood–brain
barrier. Also the inﬂux constant K1 of FDHT (ca. 0.5 ml/g/min) calculat-
ed by compartmental modeling does not suggest any impaired tracer
delivery to the brain. Moreover, the K1 value of pituitary was in the
same range as the inﬂux constant calculated for the centrally locatedFig. 4. Average Logan (left) and Patlak plots (right) of interparietal bone, bed nucleus of stri
rats (n = 4).brain regions. Thus, impaired blood–brain barrier permeability does
not seem to be the major contributor to the poor brain uptake of [18F]
FDHT in the brain.
Another cause for the lowbrain uptake of [18F]FDHT could be the fast
metabolism of the tracer. This study showed that [18F]FDHT is indeed
rapidly [15] metabolized in rats. In human, DHT is mainly bound to
sex hormone binding globulin (SHBG) and to lesser extent to albumin,
which protect the steroid from degradation. A potential cause for the
fast in-vivo degradation of [18F]FDHT observed in this study could be
the absence of SHBG in rats [16]. Radio-TLC of rat plasma showed that
all metabolites of [18F]FDHT were more polar than the parent com-
pound. Although we did not identify the nature of these metabolites,
it is expected that the main metabolites consist of glucuronides or sul-
fates of the tracer, which are unlikely to penetrate the blood–brain bar-
rier. Beattie and coworkers have isolated the radiolabelled metabolites
of [18F]FDHT from human serum and exposed them in-vitro to CWR22
cells [15]. They showed that the radiolabeled metabolites of [18F]FDHT
could not enter the cells or bind to the cell membrane. If the [18F]
FDHT metabolites cannot cross the cell membrane, it seem plausible
that they also cannot penetate the blood–brain barrier. A limitation of
our study was that we were not able to measure the percentage of
[18F]FDHT metabolites in the brain, because the intensity of the signalsa terminalis (BDNS) and occipital/temporal/parietal cortices (OTP Cortex) of Sham ORC
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567M.A. Khayum et al. / Nuclear Medicine and Biology 42 (2015) 561–569for both the intact tracer and the metabolites was below the limit of
quantiﬁcation. Taken together, poor availability of the intact tracer in
plasma due to rapid metabolism seems to contribute to the low brain
uptake of [18F]FDHT. This hypothesis is supported by the observation
that the sham-orchiectomized group revealed signiﬁcantly slower
metabolism of [18F]FDHT and a trend towards higher brain uptake
(SUV) than both the orchiectomized groups. It remains unclear why
sham-orchiectomized rats show slower tracer metabolism than
orchiectomized animals. Possibly, competition between endogenous
androgens and the PET tracer for the metabolising enzymes, or up-
regulation of metabolising enzymes in orchiectomized rats could play
a role. Studies in pig have shown that castration causes an increase in
the expression of hydroxysteroid hydrogenases in the liver [17,18].
These enzymes play an important role in the metabolism of DHT, as
they catalyse the conversion of DHT into 5α-androstan-3α/β,17β-diol,
which is furthermetabolised into the corresponding glucuronide by uri-
dine diphosphate glucuronyl transferase [19].
In addition to the metabolites found in plasma, [18F]FDHT is likely
also degraded by deﬂuorination. The accumulation of free [18F]ﬂuoride
could account for the increasing uptake of radioactivity in the cranial
bones over time. Accumulation of activity in the cranial bones is signif-
icantly higher in sham-orchiectomized rats than in both orchiectomized
groups. Orchiectomy can cause an increase in the activity of the meta-
bolic liver enzymes, resulting in increased tracer metabolism in the
orchiectomized groups. In sham-orchiectomized animals, more intact
tracer remains available that can release more free ﬂuoride, which sub-
sequently can accumulate in the bone.
Extensive deﬂuorination of [18F]FDHT has previously already
been observed in rats [9], but not in non-human primates [20].
Likewise, we did not observe any substantial bone uptake in our clin-
ical [18F]FDHT PET images either (unpublished data). In contrast to
primates, rats do not have SHBG in their plasma. This plasma protein
binds 18F-labeled steroids like [18F]FDHT and [18F]FES and protects
them from degradation. Because of the species differences in meta-
bolic stability, it may still be warranted to investigate the feasibility
of brain AR imaging in primates.
Since the accumulation of [18F]ﬂuoride in the cranial bones is located
very close to the brain and the spatial resolution of the PET camera is
limited (1.35 mm in the center of the ﬁeld of view), the tracer uptake
in peripheral rat brain areas is likely affected by spill-over of radioactiv-
ity from the bones into the brain. Indeed, the PET imaging data demon-
strated that the tracer uptake (SUV) in brain regions close to the bones
was generally higher than tracer uptake in centrally located brain re-
gions. Moreover, PET indicated that tracer uptake in the brainstem
was signiﬁcantly higher in sham-orchiectomized rats, mimicking the
differences observed in cranial bones. These observations were not
found in the ex-vivo biodistribution results, suggesting that the effect
were related to the imaging technique.
Kinetic modeling studies showed that kinetics in brain areas lying
close to the cranial bones, such as amygdala, cerebellum, frontal cortex,
occipital, temporal, parietal cortex and pituitary, could be better ﬁtted
with Patlak analysis, suggesting irreversible tracer kinetics. Likewise,
tracer kinetics in the cranial bones could also bewell describedby Patlak
graphical analysis. On the other hand, Logan analysis gave better ﬁts for
central brain regions like BNST, thalamus, striatum, hippocampus and
hypothalamus, indicating that tracer uptake in these regions shows re-
versible kinetics. These results support the presence of a substantial
spill-over effect from the irreversibly trapped radioactivity in the
bones into the ROIs of the peripheral brain regions. Therefore, we elim-
inated the peripheral brain regions from the PET image analysis and
pharmacokinetic modeling.
Kinetic modeling showed that the tracer uptake in the central brain
regions could be well described by the 1TCM. In fact, model ﬁts were
more stable for the 1TCM than for 2TRCM and the 1TCM provided VT
values with less variability. Moreover, the BPND calculated with the
2TRCM also showed substantial variability between individual animal
568 M.A. Khayum et al. / Nuclear Medicine and Biology 42 (2015) 561–569within a single group, probably because of the low values for k3 and k4.
A plausible explanation for the high variability in the results of the
2TRCM could be a low expression level of the target receptor in the
brain. Consequently, only a small fraction of the tracer in the brain is re-
ceptor bound (second tissue compartment). These observations are
supported by receptor binding studies that show that the number of
high-afﬁnity AR in the brain is substantially lower than in the ventral
prostate [21,22].
Despite the higher expression of AR in the ventral prostate than in the
brain, we could not detect any signiﬁcant inhibition of [18F]FDHT uptake
in the prostate by androgens in sham-orchiectomized or DHT-treated
rats. In contrast, Liu et al. [9] showed in an ex-vivo biodistribution study
that [18F]FDHT uptake in the prostate was approximately 70% reduced
by co-injection of the tracer with testosterone, although no statistical
analysis of this effect was provided. This apparent discrepancy between
the results of the two studies can be explained by major differences in
the experimental procedures, including differences in rat strain (Sprague
Dawley vs. Wistar-Unilever), body weight (175 g vs. 350 g, reﬂecting age
differences), anesthesia (ether vs. isoﬂuran), time point of termination
(2 h vs. 90 min p.i.) and blocker (0.2 mg/kg testosterone vs. 1 mg/kg
DHT). However, probably the most important difference between the
studies is the method of androgen deprivation (diethylstilbestrol for
24 h vs. orchiectomy for 15 days). Greenstein et al. [21] found that the
androgen receptor expression in the ventral prostate – but not in the
brain – strongly depends on the time after orchiectomy. After 0.75 days
of androgen deprivation, AR density in the prostatewas about 2.5-fold in-
creased, whereas AR density was normalized again after 21 days. This
suggests that the AR expression in the prostate was substantially higher
in the animal model used by Liu and coworkers than in the animals in
our study [9]. Another important difference between the studies, is the ar-
terial blood sampling during the PET scan. In our study, 16 blood samples
of approximately 0.1 - 0.2mlwere taken to construct a plasma input func-
tion for modeling. As a result, approximately 2 ml of blood, including a
substantial amount of the injected radioactivity, was withdrawn from
the rat. Because of some variation in the volume of the blood samples,
the sampling protocol has probably led to an increase in the inter-
individual variability in the tissue uptake of the tracer.
In this study, we also found that [18F]FDHT uptake in the brain is not
signiﬁcantly affected by endogenous androgens, nor could administra-
tion of a 1 mg/kg dose of DHT signiﬁcantly reduced tracer uptake.
These results indicate that speciﬁc AR-mediated uptake could not be de-
tected by [18F]FDHT PET. Our results are in agreement with an AR bind-
ing study with [3H]DHT [23]. This study also could not detect any
signiﬁcant differences in AR-mediated binding in the brain of castrated
and non-castrated rats.Moreover, androgen treatment did not have any
effect on AR binding in that study either.
Instead of AR speciﬁc binding, a tendency towards higher brain up-
take in the sham-orchiectomized rats (and to a lesser extend in DHT-
treated rats) was observed. A potential explanation for this tendency
could be that the tonic levels of endogenous androgens in sham-
orchiectomized rats and the short exposure to DHT in DHT-treated
rats have increased the tracer delivery to the brain. This hypothesis is
supported by the observation by Azad et al. [24] that cerebral perfusion
is reduced in hypogonadal men. This effect on cerebral perfusion can be
reverse by the administration of testosterone.
In situ hybridization studies on rat brain slices showed that AR ex-
pression varies between brain regions; it is highest in areas like amyg-
dala, hippocampus, hypothalamus, BNST, brainstem and cerebellum
[25]. In the current study, however, we could not ﬁnd any correlation
between [18F]FDHT uptake (SUV, BP or VT) and published expression
levels of AR in the rat brain [25] (data not shown). In this context it
should be noted that AR expression in the brain is often restricted to
small regions like medial preoptic, arcurate, and ventromedial nuclei
of the hypothalamus, the medial nucleus of the amygdala and the CA-
1 hippocampus [26]. The spatial resolution of the small animal PET cam-
era is not sufﬁcient to accurately visualize these small areas andconsequently any speciﬁc signal from these small regions would be
averaged with the surrounding tissue in the same voxel, yielding a
substantial partial volume effect. The low expression levels in the
brain, the small areas in which the receptors are expressed and the
extensivemetabolism of the tracer in rats seem to bemajor contributors
to the lack of speciﬁc binding found in this [18F]FDHT PET study.
5. Conclusion
In this study, we evaluated [18F]FDHTPET as a tool to quantify AR ex-
pression in the brain. Our results show that [18F]FDHT is rapidly
metabolized. Uptake of [18F]FDHT in the rat brain is low and no speciﬁc
binding to the AR could be detected. Taken together, these results
indicate that [18F]FDHT PET is not a suitable technique to monitor AR
expression in the rat brain.
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